SOR-C13 TFA
产品介绍 | SOR-C13 TFA,一种羧基末端截短肽,是一种高亲和力的 TRPV6 拮抗剂,IC50 值为 14 nM。TRPV6 是一种非电压门控钙通道,与乳腺癌的恶性肿瘤和预后不良有关。SOR-C13 TFA 具有抗癌活性。 | ||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
生物活性 | SOR-C13 TFA, a carboxy-terminal truncated peptide, is a high-affinity TRPV6 antagonist with an IC50 value of 14 nM. TRPV6 is a non-voltage gated calcium channel that is associated with malignancy and poor prognosis in breast cancer. SOR-C13 TFA has anticancer activity. | ||||||||||||||||
体外研究 | |||||||||||||||||
体内研究 |
SOR-C13 (腹腔给药; 400, 600, 800 mg/kg; 每天; 第 1 至 12 天) TFA 可有效抑制雌性 NOD/SCID 小鼠 SKOV-3 细胞肿瘤的生长。 西域 has not independently confirmed the accuracy of these methods. They are for reference only.
| ||||||||||||||||
体内研究 |
SOR-C13 (腹腔给药; 400, 600, 800 mg/kg; 每天; 第 1 至 12 天) TFA 可有效抑制雌性 NOD/SCID 小鼠 SKOV-3 细胞肿瘤的生长。 西域 has not independently confirmed the accuracy of these methods. They are for reference only.
| ||||||||||||||||
性状 | Solid | ||||||||||||||||
溶解性数据 |
In Vitro:
H2O : 100 mg/mL (59.53 mM; Need ultrasonic) 配制储备液
*
请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 | ||||||||||||||||
运输条件 | Room temperature in continental US; may vary elsewhere. | ||||||||||||||||
储存方式 |
Sealed storage, away from moisture and light
*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light) | ||||||||||||||||
参考文献 |
|